

# Complex PCI 2019

## Case Presentation III

# Role of Optical Coherence Tomography in Primary Percutaneous Coronary Intervention

29<sup>th</sup> November 2019


Dr. Jacky, Kit Chan

Consultant Cardiologist




The University of Hong Kong Shenzhen Hospital

# Case History



- M/65. Heavy smoker. Good past health. No other CAD risk factors.
- Admitted for chest pain for 2 days. ECG: STE / TWI V1-4.
- Echo: Normal. Troponin T 0.623ng/ml (NR: 0-0.014ng/ml). LDL 2.00mmol/L. FG: 5.57mmol/L.



# Coronary Angiogram




# Coronary Angiogram




# MINOCA ? Coronary Spasm ?


**No chest pain**




**Recurrent chest pain**




# OCT – LAD to LM




LM




# OCT – LAD to LM




Proximal LAD




Ostial LAD – Culprit Lesion



Mid LAD




# PCI to Ostial - Proximal LAD



GC: 6F EBU3.5 / GW: Runthrough & Sion / Stent: Xience Xpedition 3.5\*18mm / Balloon: NCsprinter3.5\*9mm




# Final Angiography




# Final ECG

**Pre PCI ECG during chest pain**



**Post PCI ECG – No chest pain**



# Roles of OCT in Primary PCI

Pre-PCI  
Procedural planning

Plaque morphology  
(e.g. Calcium / TIFA /  
Thrombus load)  
Reference lumen  
diameter / stent sizing /  
length






During PCI  
Stent Deployment &  
Optimization

Optimizing  
Landing zone  
Stent expansion

Post-PCI  
Complication & Post  
procedural assessment




Stent apposition  
Stent expansion/ MSA  
Stent edge dissection  
Tissue protrusion

# Pre-PCI Lesion Assessment





Stent sizing:  
 If EEL visible > 180° → Use the smallest of the proximal / distal reference EEL-EEL diameter and down size to the nearest 0.25mm  
 If EEL visible < 180° or not seen → Use the reference vessel luminal diameter

# Intra-procedural and Post PCI OCT Guided Stent Deployment



**Stent expansion:**  
If EEL visible > 180° → MSA in both proximal and distal halves of the stent ≥90% relative to the closest average MLA in reference segments  
If EEL visible < 180° or not seen → Aim MSA > 4.5mm<sup>2</sup>





# Role of OCT in delineating the mechanism of STEMI

- Plaque rupture
- Thrombus
- In-stent restenosis / Stent thrombosis
- Neoatherosclerosis
- Stent fracture
- Spontaneous coronary artery dissection
- **Plaque erosion with intact fibrous cap**

# Plaque Erosion vs Plaque Rupture

Lipid plaque  
with fibrous cap rupture

## A Plaque rupture





Plaque Rupture =

Fibrous cap discontinuity with a communication between the lumen and the inner core of plaque or with cavity formation within the plaque

Thrombus overlying  
an intact fibrous cap

## B Plaque erosion



Plaque Erosion =

- Intact & visualized plaque with overlying thrombus or
- Luminal surface irregularity at the culprit lesion without thrombus or
- Attenuation of the underlying plaque by thrombus without superficial lipid or calcification immediately proximal or distal to the site of thrombus

# Plaque Erosion in STEMI

Plaque erosion with intact fibrous cap → accounts for 25% to 40% of ACS

J Am Coll Cardiol. 2013;62:1748–1758.  
JACC Cardiovasc Interv. 2015;8:1166–1176.  
Eur Heart J. 2013;34:719–728.





ACS patients with plaque erosion might be treated conservatively without stenting

Eur Heart J. 2017;38:792–800.  
JACC Cardiovasc Imaging. 2013;6:283–287.  
Arch Cardiovasc Dis. 2018;111:666–677  
J Am Coll Cardiol Img 2013;6:283–7




# Clinical and Laboratory Predictors for Plaque Erosion in Patients With Acute Coronary Syndromes

Erika Yamamoto, MD, PhD; Taishi Yonetsu, MD; Tsunekazu Kakuta, MD, PhD; Tsunenari Soeda, MD, PhD; Yoshihiko Saito, MD, PhD; Bryan P. Yan, MD; Osamu Kurihara, MD, PhD; Masamichi Takano, MD, PhD; Giampaolo Niccoli, MD, PhD; Takumi Higuma, MD, PhD; Shigeki Kimura, MD, PhD; Yoshiyasu Minami, MD, PhD; Junya Ako, MD, PhD; Tom Adriaenssens, MD, PhD; Niklas F. Boeder, MD; Holger M. Nef, MD; Francesco Fracassi, MD; Tomoyo Sugiyama, MD, PhD; Hang Lee, PhD; Filippo Crea, MD; Takeshi Kimura, MD, PhD; James G. Fujimoto, PhD; Valentin Fuster, MD, PhD; Ik-Kyung Jang, MD, PhD



# 5 Independent Predictors of Plaque Erosion



Age < 68 y

Anterior ischemia

No DM



Hemoglobin > 15.0 g/dL

Normal renal function

In-hospital mortality : Plaque erosion group 0.6% vs plaque rupture group 1.5% (p=0.15)

Stenting: Plaque erosion group 92.5% vs plaque rupture group 97.7% (p<0.001)

# OCT-Based Diagnosis and Management of STEMI Associated With Intact Fibrous Cap




# Clinical Significance of the Presence or Absence of Lipid-Rich Plaque Underneath Intact Fibrous Cap Plaque in Acute Coronary Syndrome

Masahiro Hoshino, MD; Taishi Yonetsu, MD; Eisuke Usui, MD; Yoshihisa Kanaji, MD; Hiroaki Ohya, MD; Yohei Sumino, MD; Masao Yamaguchi, MD; Masahiro Hada, MD; Rikuta Hamaya, MD; Yoshinori Kanno, MD; Tadashi Murai, MD, PhD; Tetsumin Lee, MD; Tsunekazu Kakuta, MD, PhD

Plaque Rupture (PR)  
N = 328 (64%)


99% had LRP



IFC = Intact fibrous cap  
LRP = Lipid-rich plaque  
PR = Plaque rupture

## Study population


Registry of OCT during PCI in Tsuchiura Kyodo General Hospital (n=3192) between November 2008 and May 2017



No Plaque Rupture  
N = 182 (36%)



IFC – LRP (67%)




IFC – No LRP (33%)

# Clinical Significance of the Presence or Absence of Lipid-Rich Plaque Underneath Intact Fibrous Cap Plaque in Acute Coronary Syndrome

Masahiro Hoshino, MD; Taishi Yonetsu, MD; Eisuke Usui, MD; Yoshihisa Kanaji, MD; Hiroaki Ohya, MD; Yohei Sumino, MD; Masao Yamaguchi, MD; Masahiro Hada, MD; Rikuta Hamaya, MD; Yoshinori Kanno, MD; Tadashi Murai, MD, PhD; Tetsumin Lee, MD; Tsunekazu Kakuta, MD, PhD


**Intact Fibrous Cap without Lipid-rich Plaque** = Independent predictor of better prognosis  
 → lower MACEs vs Plaque Rupture and Intact Fibrous Cap group with Lipid-rich Plaque.



Diameter stenosis  
 Plaque erosion gp  
 77.0+/-20.2%  
 Vs  
 Plaque rupture gp  
 83.2+/-18.4%


MACE = Cardiac death, MI, Revascularization → Occurred in 16.7% at median follow-up duration of 621d

# Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study)



- In all ACS patients with OCT evaluated:  
~ 25% had plaque erosion without rupture
- In patients with plaque erosion  
~ 60% had diameter stenosis <70%  
Mean diameter stenosis 56.7+/-10.4mm
- In patients with plaque erosion & diameter stenosis <70% → anti-thrombotic / no stenting
- OCT repeated in 1 month

# Clinical outcome, absolute and percentage thrombus volume reduction at 1 month OCT follow-up in patients with plaque erosion & <70% diameter stenosis



Outcome: 78% patients had >50% reduction of thrombus volume at 1 month. ~ 40% no visible thrombus at 1 month

No reported CV death, re-MI, ACS hospitalization, clinically-driven TVR, stroke. 1 patient died of GI bleeding

# Conclusion

1. OCT has pivotal roles in STEMI & Primary PCI in delineating the disease mechanism and procedure optimization
2. Plaque erosion with intact fibrous cap (PE IFC) accounts for 25-40% of ACS
3. 40-60% of PE IFC had sub-critical coronary stenosis, which could be managed conservatively without stenting & carries favorable prognosis



# Discussion

- Role of routine OCT in stable STEMI patients –
  - especially in non-occlusive lesions after thrombectomy
- Pathophysiology of plaque erosion with intact fibrous cap
- Optimal strategy in managing STEMI patients with PE IFC :
  - Conservative medical therapy vs stenting ?